يعرض 1 - 10 نتائج من 50 نتيجة بحث عن '"Mukhametshina Guzel"', وقت الاستعلام: 1.46s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

    المؤلفون: Rugo, Hope S, Pennella, Eduardo J, Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D, Abesamis-Tiambeng, Maria Luisa T, Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F

    المصدر: Breast Cancer Research and Treatment. 188(2)

    مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Receptor, ErbB-2, Survival Analysis, Trastuzumab, Treatment Outcome, Biosimilar, Metastatic breast cancer, Overall survival, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis

    وصف الملف: application/pdf

    الوصول الحر: https://escholarship.org/uc/item/4x95623rTest

    View record in eScholarship

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

    المؤلفون: Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won, Antón-Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, Gelmon, Karen A., Koynova, Tatyana, Popov, Vasil, Timcheva, Constanta, Tomova, Antoaneta, Eisen, Andrea, Gelmon, Karen, Lemieux, Julie, Augereau, Paule, Bazan, Fernando, Becuwe, Célia, Bourgeois, Hugues, Chakiba, Camille, Chehimi, Mohamad, Cheneau, Caroline, Dalenc, Florence, de Guillebon, Eléonore, de La Motte Rouge, Thibault, Frenel, Jean-Sébastien, Grenier, Julien, Hardy-Bessard, Anne Claire, Lamy, Regine, Levy, Christelle, Lortholary, Alain, Mailliez, Audrey

    المساهمون: AstraZeneca, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

    المصدر: Breast Cancer Research and Treatment ; ISSN 0167-6806 1573-7217

    مصطلحات موضوعية: Cancer Research, Oncology

    الإتاحة: https://doi.org/10.1007/s10549-023-07165-xTest

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

    المؤلفون: Poddubskaya, Elena, Gelmon, Karen A., Gibson, Isabel, Baria, Katherine, John, Ellie, Antón-Torres, Antonio, Park-Simon, Tjoung-Won, Timcheva, Constanta V., Aksoy, Sercan, Mukhametshina, Guzel, Sohn, Joo Hyuk, Jankowski, Tomasz, Swampillai, Angela, Kemp, Zoe, Gonçalves, Anthony, Bourgeois, Hughes, You, Benoit, Eisen, Andrea F., Park, Yeon Hee, O’Shaughnessy, Joyce, Labidi-Galy, Intidhar, Delaloge, Suzette, Couch, Fergus J., Fasching, Peter A., Balmaña, Judith

    العلاقة: 601068d3-9118-46a7-88c8-aced101ffd83; https://avesis.hacettepe.edu.tr/publication/details/601068d3-9118-46a7-88c8-aced101ffd83/oaiTest

    الإتاحة: https://doi.org/10.1007/s10549-023-07165-xTest
    https://avesis.hacettepe.edu.tr/publication/details/601068d3-9118-46a7-88c8-aced101ffd83/oaiTest

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

    المؤلفون: Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O'Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won

    المصدر: Breast Cancer Research & Treatment; Apr2024, Vol. 204 Issue 2, p237-248, 12p


    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    المؤلفون: Gelmon, Karen A., Fasching, Peter A., Couch, Fergus J., Balmaña, Judith, Delaloge, Suzette, Labidi-Galy, Intidhar, Bennett, James, McCutcheon, Susan, Walker, Graham, O'Shaughnessy, Joyce, Collaborating Investigator, Timcheva, Constanta, Tomova, Antoaneta, Eisen, Andrea, Lemieux, Julie, Bazan, Fernando, Bourgeois, Hugues, Chakiba, Camille, Chehimi, Mohamad, Dalenc, Florence, De La Motte Rouge, Thibault, Frenel, Jean-Sébastien, Gonçalves, Anthony, Hardy-Bessard, Anne Claire, Lamy, Regine, Levy, Christelle, Lortholary, Alain, Mailliez, Audrey, Medioni, Jacques, Patsouris, Anne, Spaeth, Dominique, Teixeira, Luis, Tennevet, Isabelle, Villanueva, Cristian, You, Benoit, Ettl, Johannes, Gerber, Bernd, Hoffmann, Oliver, Park-Simon, Tjoung-Won, Reinisch, Mattea, Tio, Joke, Wimberger, Pauline, Boer, Katalin, Ballestrero, Alberto, Bianchini, Giampaolo, Biganzoli, Laura, Bordonaro, Roberto, Cognetti, Francesco, De Laurentiis, Michelino, De Placido, Sabino, Guarneri, Valentina, Montemurro, Filippo, Naso, Giuseppe, Santoro, Armando, Zamagni, Claudio, Kim, Seung-Jin, Nakamura, Seigo, Chae, Yee Soo, Cho, Eun Kyung, Hyun, Kim Jee, Im, Seock-Ah, Lee, Keun Seok, Park, Yeon Hee, Sohn, Joo Hyuk, Byrski, Tomasz, Huzarski, Tomasz, Kukielka-Budny, Bozena, Nowecki, Zbigniew, Szoszkiewicz, Renata, Tarnawski, Rafal, Dvornichenko, Viktoria, Moiseenko, Fedor, Mukhametshina, Guzel, Poddubskaya, Elena, Popova, Ekaterina, Tarasova, Anna, Vats, Anna, Adamo, Bárbara, Conejero, Raquel Andrés, Torres, Antonio Antón, Gelpi, Judith Balmaña, Fernández, Nieves Díaz, González, Alejandro Falcón, Garcia, Juan, Lorenzo-Lorenzo, Isabel, Antón, Fernando Moreno, Santisteban, Marta, Stradella, Agostina, Huang, Chiun-Sheng, Aksoy, Sercan, Arslan, Cagatay, Artac, Mehmet, Aydiner, Adnan, Ozyilkan, Ozgur, Sezer, Emel, Armstrong, Anne, Barrett, Sophie, Borley, Annabel, Kemp, Zoe, Michie, Caroline, Mukesh, Mukesh, Perren, Timothy, Swampillai, Angela, Young, Tammy

    المساهمون: 임석아, Im, Seock-Ah

    مصطلحات موضوعية: PREVALENCE, MUTATIONS, CHEMOTHERAPY, BRCA1 gene, BRCA2 gene, Breast cancer, Effectiveness, Germline mutation, Metastatic, Olaparib, Progression-free survival, Treatment outcome

    العلاقة: European Journal of Cancer, Vol.152, pp.68-77; 158584; https://hdl.handle.net/10371/179226Test; 000678059500008; 2-s2.0-85107637276

    الإتاحة: https://doi.org/10.1016/j.ejca.2021.03.029Test
    https://hdl.handle.net/10371/179226Test

    View record in BASE

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study

    المؤلفون: de Marinis, Filippo, Laktionov, Konstantin K., Poltoratskiy, Artem, Egorova, Inna, Hochmair, Maximilian, Passaro, Antonio, Migliorino, Maria Rita, Metro, Giulio, Gottfried, Maya, Tsoi, Daphne, Ostoros, Gyula, Rizzato, Simona, Mukhametshina, Guzel Z., Schumacher, Michael, Novello, Silvia, Dziadziuszko, Rafal, Tang, Wenbo, Clementi, Laura, Cseh, Agnieszka, Kowalski, Dariusz

    المساهمون: Boehringer Ingelheim Inc

    المصدر: Lung Cancer ; volume 152, page 127-134 ; ISSN 0169-5002

    مصطلحات موضوعية: Cancer Research, Pulmonary and Respiratory Medicine, Oncology

    الإتاحة: https://doi.org/10.1016/j.lungcan.2020.12.011Test
    https://api.elsevier.com/content/article/PII:S0169500220307285?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0169500220307285?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

    المؤلفون: Alexeev, Sergey M., Khorinko, Andrey V., Mukhametshina, Guzel Z., Shelepen, Konstantin G., Burdaeva, Olga N., Kulik, Sergey A., Satheesh, Chiradoni Thugappa, Srivastava, Kirti, Vikranth, Mummaneni, Kryukov, Fedor, Paltusova, Anastasia N., Shustova, Mariya S., Ivanov, Roman A.

    المصدر: BMC Cancer ; volume 20, issue 1 ; ISSN 1471-2407

    مصطلحات موضوعية: Cancer Research, Genetics, Oncology

    الإتاحة: https://doi.org/10.1186/s12885-020-07247-9Test

    View record in BASE

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Candidate markers of homologous recombination deficiency for triple negative breast cancer

    المؤلفون: Havrysh Kristina Vladislavovna, Mukhametshina Guzel Zinnurovna, Petrov Semen Venediktovich, Safina S., Kiyamova Ramziya Gallyamovna

    المساهمون: Институт фундаментальной медицины и биологии, Казанский федеральный университет

    مصطلحات موضوعية: homologous recombination deficiency, triple negative breast cancer, predictive biomarkers, Медицина и здравоохранение

    العلاقة: ANNALS OF ONCOLOGY; suppl_9; 29; http://rour.neicon.ru:80/xmlui/bitstream/rour/187191/1/nora.pdfTest; Havrysh K. Candidate markers of homologous recombination deficiency for triple negative breast cancer / K. Havrysh, G. Mukhametshina, S. Safina, S. Petrov, R. Kiyamova // Annals of Oncology - 2018. - Vol. 29. - Issue suppl_9. - mdy441.025.; https://openrepository.ru/article?id=187191Test

    الإتاحة: https://openrepository.ru/article?id=187191Test

    View record in BASE

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

    المؤلفون: Herbst, Roy S., Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Wang, Jie, Kato, Terufumi, Goldman, Jonathan W., Laktionov, Konstantin, Kim, Sang-We, Yu, Chong-Jen, Vu, Huu Vinh, Lu, Shun, Lee, Kye Young, Mukhametshina, Guzel, Akewanlop, Charuwan, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A.

    المصدر: Journal of Clinical Oncology; 4/1/2023, Vol. 41 Issue 10, p1830-1840, 11p


    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer ; A Randomized Clinical Trial

    المؤلفون: Rugo, Hope S., Barve, Abhijit, Waller, Cornelius F., Hernandez-Bronchud, Miguel, Herson, Jay, Yuan, Jinyu, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Loganathan, Subramanian, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Ray, Sirshendu, Yanez Ruiz, Eduardo P., Pennella, Eduardo

    المصدر: JAMA ; volume 317, issue 1, page 37 ; ISSN 0098-7484

    الإتاحة: https://doi.org/10.1001/jama.2016.18305Test
    http://jamanetwork.com/journals/jama/fullarticle/2590051Test

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث